Next Article in Journal
Lorlatinib Effectiveness and Quality-of-Life in Patients with ALK-Positive NSCLC Who Had Failed Second-Generation ALK Inhibitors: Canadian Real-World Experience
Next Article in Special Issue
Ampullary Cancer: Histological Subtypes, Markers, and Clinical Behaviour—State of the Art and Perspectives
Previous Article in Journal
Peripheral Neuropathy Potentially Associated to Poly (ADP-Ribose) Polymerase Inhibitors: An Analysis of the Eudravigilance Database
Previous Article in Special Issue
Treatment Settings and Outcomes with Regorafenib and Trifluridine/Tipiracil at Third-Line Treatment and beyond in Metastatic Colorectal Cancer: A Real-World Multicenter Retrospective Study
 
 
Review

Article Versions Notes

Curr. Oncol. 2023, 30(7), 6546-6558; https://doi.org/10.3390/curroncol30070480
Action Date Notes Link
article xml file uploaded 7 July 2023 13:01 CEST Original file -
article xml uploaded. 7 July 2023 13:01 CEST Update https://www.mdpi.com/1718-7729/30/7/480/xml
article pdf uploaded. 7 July 2023 13:01 CEST Version of Record https://www.mdpi.com/1718-7729/30/7/480/pdf
article html file updated 7 July 2023 13:03 CEST Original file -
article html file updated 20 July 2023 21:06 CEST Update https://www.mdpi.com/1718-7729/30/7/480/html
Back to TopTop